Daniel Ricklin

发表

Protection of host cells by complement regulators

John D Lambris, D. Ricklin, J. Lambris, 2016, Immunological reviews.

Complement: a key system for immune surveillance and homeostasis

John D Lambris, D. Ricklin, J. Lambris, 2010, Nature Immunology.

The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology

D. Ricklin, C. Lamers, Carla Johanna Plüss, 2021, Frontiers in Immunology.

Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood

John D Lambris, D. Ricklin, J. Lambris, 2016, The Journal of Immunology.

Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule

N. Martinelli, D. Ricklin, J. Lambris, 2019, Haematologica.

Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application.

John D Lambris, J. Lambris, G. Hajishengallis, 2016, Seminars in immunology.

Genetic and Intervention Studies Implicating Complement C3 as a Major Target for the Treatment of Periodontitis

John D Lambris, D. Ricklin, J. Lambris, 2014, The Journal of Immunology.

Treatment of Periodontitis Complement C3 as a Major Target for the Genetic and Intervention Studies Implicating

John D Lambris, D. Ricklin, J. Lambris, 2014 .

Developments in anti‐complement therapy; from disease to clinical trial

D. Ricklin, D. Kavanagh, C. Harris, 2018, Molecular immunology.

Complement Deficiency Promotes Cutaneous Wound Healing in Mice

John D Lambris, E. Grice, D. Ricklin, 2015, The Journal of Immunology.

This information is current as Wound Healing in Mice Complement Deficiency Promotes Cutaneous

E. Grice, D. Ricklin, J. Lambris, 2014 .

Complement component C3 – The “Swiss Army Knife” of innate immunity and host defense

John D Lambris, D. Ricklin, J. Lambris, 2016, Immunological reviews.

Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms

John D. Lambris, Daniel Ricklin, John D Lambris, 2013, The Journal of Immunology.

Progress and Trends in Complement Therapeutics.

Daniel Ricklin, John D Lambris, D. Ricklin, 2013, Advances in experimental medicine and biology.

Disorders: Pathophysiological Mechanisms Complement in Immune and Inflammatory

John D Lambris, J. Lambris, Daniel Ricklin, 2022 .

Disorders: Pathophysiological Mechanisms Complement in Immune and Inflammatory

John D Lambris, D. Ricklin, J. Lambris, 2022 .

Compstatin: a complement inhibitor on its way to clinical application.

John D Lambris, J. Lambris, Daniel Ricklin, 2008, Advances in experimental medicine and biology.

Recent developments in low molecular weight complement inhibitors.

John D Lambris, D. Ricklin, J. Lambris, 2009, Molecular immunology.

The Extracellular Adherence Protein from Staphylococcus aureus Inhibits the Classical and Lectin Pathways of Complement by Blocking Formation of the C3 Proconvertase

John D Lambris, D. Ricklin, J. Lambris, 2014, Journal of Immunology.

Blocking Formation of the C3 Proconvertase and Lectin Pathways of Complement by Inhibits the Classical Staphylococcus Aureus the Extracellular Adherence Protein From

John D Lambris, J. Lambris, K. Ramyar, 2022 .

Blocking Formation of the C3 Proconvertase and Lectin Pathways of Complement by Inhibits the Classical Staphylococcus Aureus the Extracellular Adherence Protein From

John D Lambris, J. Lambris, K. Ramyar, 2022 .

Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40.

John D Lambris, Lu Wang, D. Ricklin, 2016, Clinical immunology.

Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy

G. Coukos, D. Ricklin, Aizhi Zhao, 2018, Cancer Immunology, Immunotherapy.

Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy

D. Ricklin, Aizhi Zhao, Qirui Wang, 2016, Cancer Immunology, Immunotherapy.

Applying complement therapeutics to rare diseases.

John D Lambris, D. Ricklin, J. Lambris, 2015, Clinical immunology.

Complement evasion by human pathogens

John D. Lambris, Daniel Ricklin, John D Lambris, 2008, Nature Reviews Microbiology.

Immune Responses to Biosurfaces

John D Lambris, B. Nilsson, K. Ekdahl, 2015, Advances in Experimental Medicine and Biology.

Novel mechanisms and functions of complement

Daniel Ricklin, John D Lambris, D. Ricklin, 2017, Nature Immunology.

Complement in disease: a defence system turning offensive

John D. Lambris, Daniel Ricklin, John D Lambris, 2016, Nature Reviews Nephrology.

Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape

John D Lambris, D. Ricklin, J. Lambris, 2014, Expert review of hematology.

Complement in Immune and Inflammatory Disorders: Therapeutic Interventions

John D Lambris, D. Ricklin, J. Lambris, 2013, The Journal of Immunology.

Molecular basis for complement recognition and inhibition determined by crystallographic studies of the staphylococcal complement inhibitor (SCIN) bound to C3c and C3b.

John D Lambris, D. Ricklin, J. Lambris, 2010, Journal of molecular biology.

Real-time label-free detection of complement activation products in human serum by white light reflectance spectroscopy.

Ioannis Raptis, Konstantinos Misiakos, Daniel Ricklin, 2009, Biosensors & bioelectronics.

Electrostatic contributions drive the interaction between Staphylococcus aureus protein Efb‐C and its complement target C3d

Nurit Haspel, Daniel Ricklin, John D Lambris, 2008, Protein science : a publication of the Protein Society.

Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry.

Daniel Ricklin, John D Lambris, Yoshitomo Hamuro, 2008, Molecular immunology.

Characterization of Ehp, a Secreted Complement Inhibitory Protein from Staphylococcus aureus*

John D Lambris, M. Pop, D. Ricklin, 2007, Journal of Biological Chemistry.

A structural basis for complement inhibition by Staphylococcus aureus

Daniel Ricklin, John D Lambris, Paola Magotti, 2007, Nature Immunology.

C 3 d protein Efb-C and its complement targetStaphylococcus aureus Electrostatic contributions drive the interaction between data

L. Kavraki, N. Haspel, D. Ricklin, 2022 .

New milestones ahead in complement-targeted therapy.

John D Lambris, D. Ricklin, J. Lambris, 2016, Seminars in immunology.

Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies.

John D Lambris, P. Nilsson, B. Nilsson, 2011, Advanced drug delivery reviews.

Structural and functional implications of the complement convertase stabilized by a staphylococcal inhibitor

John D Lambris, D. Ricklin, J. Lambris, 2009, Nature Immunology.

Cutting Edge: Members of the Staphylococcus aureus Extracellular Fibrinogen-Binding Protein Family Inhibit the Interaction of C3d with Complement Receptor 21

John D Lambris, D. Ricklin, J. Lambris, 2008, The Journal of Immunology.

Attenuation of Staphylococcus aureus–Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb

John D Lambris, D. Ricklin, J. Lambris, 2015, The Journal of Immunology.

Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency.

John D Lambris, D. Ricklin, J. Lambris, 2011, Molecular immunology.

The renaissance of complement therapeutics

John D Lambris, D. Ricklin, J. Lambris, 2018, Nature Reviews Nephrology.

Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery.

John D Lambris, D. Ricklin, J. Lambris, 2017, Trends in immunology.

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.

John D Lambris, D. Ricklin, J. Lambris, 2017, Blood.

Compstatin: a C3‐targeted complement inhibitor reaching its prime for bedside intervention

John D Lambris, B. Nilsson, J. Lambris, 2015, European journal of clinical investigation.

Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters.

John D Lambris, D. Ricklin, J. Lambris, 2015, Immunobiology.

Complement-targeted therapeutics

John D Lambris, D. Ricklin, J. Lambris, 2007, Nature Biotechnology.

Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock

John D Lambris, B. Nilsson, D. Ricklin, 2018, Shock.

Interactions between coagulation and complement—their role in inflammation

John D Lambris, D. Ricklin, J. Lambris, 2011, Seminars in Immunopathology.

Structure‐kinetic relationship analysis of the therapeutic complement inhibitor compstatin

John D Lambris, D. Ricklin, J. Lambris, 2009, Journal of molecular recognition : JMR.

Complement‐targeted therapeutics: An emerging field enabled by academic drug discovery

John D Lambris, D. Ricklin, J. Lambris, 2023, American journal of hematology.

Regulators of complement activity mediate inhibitory mechanisms through a common C3b‐binding mode

John D Lambris, E. Volokhina, D. Ricklin, 2016, The EMBO journal.

Structure of C3b-factor H and implications for host protection by complement regulators

John D Lambris, D. Ricklin, J. Lambris, 2009, Nature Immunology.

Structure of complement fragment C 3 b – factor H and implications for host protection by complement regulators

John D Lambris, D. Ricklin, J. Lambris, 2009 .

Complement Inhibition in a Xenogeneic Model of Interactions Between Human Whole Blood and Porcine Endothelium

John D Lambris, S. Bornstein, D. Ricklin, 2014, Hormone and Metabolic Research.

Preformed mediators of defense—Gatekeepers enter the spotlight

John D Lambris, J. Lambris, Daniel Ricklin, 2016, Immunological reviews.

Clinical promise of next-generation complement therapeutics

John D Lambris, D. Ricklin, J. Lambris, 2019, Nature Reviews Drug Discovery.

Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.

John D Lambris, J. Lambris, D. Mastellos, 2016, Molecular oral microbiology.

Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3.

John D Lambris, D. Ricklin, J. Lambris, 2016, Journal of clinical periodontology.

Local Complement-Targeted Intervention in Periodontitis: Proof-of-Concept Using a C5a Receptor (CD88) Antagonist

John D Lambris, D. Ricklin, J. Lambris, 2012, The Journal of Immunology.

Receptor (CD88) Antagonist Periodontitis: Proof-of-Concept Using a C5a Local Complement-Targeted Intervention in

John D Lambris, D. Ricklin, J. Lambris, 2012 .

Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.

D. Ricklin, Daniel Ricklin, 2012, Immunobiology.

Complement in cancer: untangling an intricate relationship

John D Lambris, A. Mantovani, D. Ricklin, 2017, Nature Reviews Immunology.

Native state of complement protein C3d analysed via hydrogen exchange and conformational sampling

Jayvee R. Abella, John D Lambris, L. Kavraki, 2018, Int. J. Comput. Biol. Drug Des..

Exploring the function of factor XIII free B subunit: Interactions with complement factors and a novel approach to identify potential binding partners

D. Ricklin, V. Schroeder, L. Jenny, 2022, Research and practice in thrombosis and haemostasis.

Inhibition of biomaterial‐induced complement activation attenuates the inflammatory host response to implantation

John D Lambris, D. Ricklin, J. Lambris, 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Complement inhibition can decrease the haemostatic response in a microvascular bleeding model at multiple levels

Murielle Golomingi, J. Dobó, G. Pál, 2023, Frontiers in immunology.

Induction of Complement C3a Receptor Responses by Kallikrein-Related Peptidase 14

E. Diamandis, M. Hollenberg, D. Ricklin, 2013, The Journal of Immunology.

Responses by Kallikrein-Related Peptidase Induction of Complement C 3 a Receptor Ricklin and

E. Diamandis, M. Hollenberg, D. Ricklin, 2013 .

Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.

John D Lambris, D. Ricklin, J. Lambris, 2012, Immunobiology.

eview argeted complement inhibition as a promising strategy for preventing nflammatory complications in hemodialysis

John D Lambris, D. Ricklin, J. Lambris, 2012 .

Tipping the balance: intricate roles of the complement system in disease and therapy

D. Ricklin, R. Pouw, R. B. Pouw, 2021, Seminars in Immunopathology.

A Structurally Dynamic N-terminal Helix Is a Key Functional Determinant in Staphylococcal Complement Inhibitor (SCIN) Proteins*

John D Lambris, D. Ricklin, J. Lambris, 2012, The Journal of Biological Chemistry.

C5a Receptor-Dependent Cell Activation by Physiological Concentrations of Desarginated C5a: Insights from a Novel Label-Free Cellular Assay

John D Lambris, P. Monk, D. Ricklin, 2012, The Journal of Immunology.

Protection of Nonself Surfaces from Complement Attack by Factor H-Binding Peptides: Implications for Therapeutic Medicine

John D. Lambris, Bo Nilsson, Daniel Ricklin, 2011, The Journal of Immunology.

MedicinePeptides: Implications for Therapeutic Complement Attack by Factor H-Binding Protection of Nonself Surfaces from

John D Lambris, B. Nilsson, K. Ekdahl, 2011 .

Structures of C3b in Complex with Factors B and D Give Insight into Complement Convertase Formation

Jin Wu, Piet Gros, Federico Forneris, 2010, Science.

From discovery to approval: A brief history of the compstatin family of complement C3 inhibitors.

D. Ricklin, G. Sfyroera, D. Mastellos, 2021, Clinical immunology.

From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.

John D Lambris, D. Ricklin, J. Lambris, 2016, Immunobiology.

Therapeutic control of complement activation at the level of the central component C3.

John D Lambris, D. Ricklin, J. Lambris, 2016, Immunobiology.

Rare Loss-of-Function Mutation in Complement Component C3 Provides Insight into Molecular and Pathophysiological Determinants of Complement Activity

John D Lambris, B. Nilsson, K. Ekdahl, 2015, The Journal of Immunology.

Conjugation to Albumin‐Binding Molecule Tags as a Strategy to Improve Both Efficacy and Pharmacokinetic Properties of the Complement Inhibitor Compstatin

John D Lambris, D. Ricklin, J. Lambris, 2014, ChemMedChem.

Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.

John D Lambris, B. Nilsson, K. Ekdahl, 2014, Biomaterials.

Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.

John D Lambris, D. Ricklin, J. Lambris, 2014, Blood.

New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties.

John D Lambris, Hongjun Bai, Hui Chen, 2013, Immunobiology.

Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin.

John D Lambris, D. Ricklin, J. Lambris, 2011, ACS chemical biology.

Determinants of Complement Activity into Molecular and Pathophysiological InsightComplement Component C 3 Provides Rare Loss-of-Function Mutation in Ekdahl

John D Lambris, B. Nilsson, K. Ekdahl, 2015 .

RED CELLS , IRON , AND ERYTHROPOIESIS Peptide inhibitors of C 3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria

John D Lambris, D. Ricklin, J. Lambris, 2014 .

Peptide inhibitors of C 3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria Supplemental Methods

John D Lambris, D. Ricklin, J. Lambris, 2013 .

Exploring the complement interaction network using surface plasmon resonance.

John D Lambris, D. Ricklin, J. Lambris, 2007, Advances in experimental medicine and biology.

C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases

P. Parren, D. Ricklin, P. Gros, 2021, Proceedings of the National Academy of Sciences.

Sweet turning bitter: Carbohydrate sensing of complement in host defence and disease

D. Ricklin, C. Harris, Rachel Hevey, 2020, British journal of pharmacology.

Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria.

Patrizia Ricci, Daniel Ricklin, John D Lambris, 2015, Blood.

Complement C 3 dg-mediated erythrophagocytosis : implications for paroxysmal nocturnal hemoglobinuria

John D. Lambris, Christoph Q. Schmidt, Patrizia Ricci, 2015 .

RED CELLS , IRON , AND ERYTHROPOIESIS Complement C 3 dg-mediated erythrophagocytosis : implications for paroxysmal nocturnal hemoglobinuria

John D Lambris, A. Risitano, S. Koutsogiannaki, 2015 .

Intracellular C4BPA Levels Regulate NF-κB-Dependent Apoptosis

T. Graeber, A. Giaccia, D. Ricklin, 2020, iScience.

Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating

John D Lambris, H. Iwata, P. Nilsson, 2012, Biomaterials.

Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy.

John D Lambris, D. Ricklin, J. Lambris, 2015, Immunobiology.

Complement in clinical medicine: Clinical trials, case reports and therapy monitoring

D. Ricklin, A. Barratt-Due, T. Mollnes, 2017, Molecular immunology.

Compstatins: the dawn of clinical C3-targeted complement inhibition.

John D Lambris, D. Ricklin, J. Lambris, 2022, Trends in pharmacological sciences.

Therapeutic targeting of the complement system

John D Lambris, D. Ricklin, J. Lambris, 2019, Nature Reviews Drug Discovery.

Analysis of Molecular Interactions by Surface Plasmon Resonance Spectroscopy

D. Ricklin, E. Muñoz, Daniel Ricklin, 2014 .

Oligohis‐tags: mechanisms of binding to Ni2+‐NTA surfaces

B. Ernst, A. Eberle, S. Knecht, 2009, Journal of molecular recognition : JMR.

Coarse-Grained Conformational Sampling of Protein Structure Improves the Fit to Experimental Hydrogen-Exchange Data

Didier Devaurs, Lydia E. Kavraki, Mark Moll, 2017, Front. Mol. Biosci..

Cellular Assay C5a: Insights from a Novel Label-Free Desarginated Physiological Concentrations of C5a Receptor-Dependent Cell Activation by

John D Lambris, P. Monk, D. Ricklin, 2012 .

Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.

John D Lambris, T. Simmet, M. Anliker, 2016, Immunobiology.

Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H–like Protein 1 Reveal Functional Determinants of Complement Regulation

John D Lambris, D. Ricklin, J. Lambris, 2016, The Journal of Immunology.

Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting Properties

John D Lambris, Hongjun Bai, D. Ricklin, 2013, The Journal of Immunology.

IMMUNOBIOLOGY Incomplete inhibition by eculizumab : mechanistic evidence for residual C 5 activity during strong complement activation

John D Lambris, D. Ricklin, J. Lambris, 2017 .

Triple-Targeting Properties Immune Inhibitor with Unique Rational Engineering of a Minimized

John D Lambris, Hongjun Bai, D. Ricklin, 2013 .

Disorders: Therapeutic Interventions Complement in Immune and Inflammatory

John D Lambris, D. Ricklin, J. Lambris, 2022 .

Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor (ASGP-R).

A. Vedani, D. Ricklin, O. Schwardt, 2009, Bioorganic & medicinal chemistry.

Diversity in the C3b Convertase Contact Residues and Tertiary Structures of the Staphylococcal Complement Inhibitor (SCIN) Protein Family*

John D Lambris, D. Ricklin, J. Lambris, 2011, The Journal of Biological Chemistry.

Allosteric inhibition of complement function by a staphylococcal immune evasion protein

Sheng Li, John D. Lambris, Daniel Ricklin, 2010, Proceedings of the National Academy of Sciences.

Advances in understanding the structure, function, and mechanism of the SCIN and Efb families of Staphylococcal immune evasion proteins.

John D Lambris, D. Ricklin, J. Lambris, 2012, Advances in experimental medicine and biology.

Complement in Action: An Analysis of Patent Trends from 1976 Through 2011

John D Lambris, J. E. Reed, D. Ricklin, 2012, Advances in experimental medicine and biology.

Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18

John D Lambris, B. Nilsson, K. Ekdahl, 2015, Thrombosis and Haemostasis.

Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation

John D Lambris, D. Ricklin, J. Lambris, 2017, Front. Immunol..

Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia.

E. M. Cook, John D Lambris, D. Ricklin, 2016, Clinical immunology.

Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS.

John D Lambris, B. Nilsson, E. Reis, 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Title: Method Development and Validation for the Quantitation of the Complement Inhibitor Cp40 in Human and Cynomolgus Monkey Plasma by UPLC-ESI-MS

E. Reis, S. Koutsogiannaki, J. V. Tuplano, 2016 .

TMA: beware of complements.

D. Ricklin, D. Cines, Daniel Ricklin, 2013, Blood.

A sweet spot to control complement-induced inflammation

John D Lambris, D. Ricklin, J. Lambris, 2012, Nature Medicine.